Boston Scientific reported positive results from the FRACTURE IDE trial for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter in patients with severely calcified coronary artery disease. The readout supports the company’s interventional cardiology franchise and may improve adoption prospects for the device. The announcement is positive for BSX, though the article provides no quantitative efficacy or safety data.
Boston Scientific reported positive results from the FRACTURE IDE trial for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter in patients with severely calcified coronary artery disease. The readout supports the company’s interventional cardiology franchise and may improve adoption prospects for the device. The announcement is positive for BSX, though the article provides no quantitative efficacy or safety data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
